Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.
ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ program raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation, and provides specialist support to a further $100M of funding managed by Brandon Capital.
Bronwyn has been a Member of the Council of the National Health & Medical Research Council since 2021. She is also currently a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) alongside a number of other advisory roles.

As a co-inventor on a patented and ASX listed digital health technology; Grace Lethlean has been actively involved in the development of health technologies from invention, through clinical trials, to commercialisation.

Grace is co-founder and Chief Product Officer of ANDHealth, Australia’s national digital health initiative, accelerating the commercialisation of evidence-based digital health technologies. Grace’s focus is on supporting digital health technologies to meet key investor, partner and customer requirements around clinical and commercial validation.

Grace also supports the sector through numerous state and national Advisory Panels and Committees, is a 2020 SuperStar of STEM, is an inventor on patents in the US and Australia, a published author on digital health commercialisation, a 2022 Churchill Fellow, investigating international best practice in digital health business support and recognised in 2024 as an AFR Women in Leadership.

Anya is co-founder of Syrona Health, a YCombinator-backed women's health platform delivering personalised care across life stages from menstrual health, fertility through menopause. Previously, she served as Head of Illumina for Startups across EMEA, directing the genomics giant's engagement with emerging biotech innovators.

A seasoned venture capital investor, Anya has led numerous strategic investments including industry pioneers Oxford Nanopore, Broken String Biosciences, and Alchemab. Her multifaceted career spans banking at Goldman Sachs, venture capital with a focus on spinouts, and entrepreneurship.

Anya holds an MPhil in Bioscience from the University of Cambridge and an MBA from Oxford University. She brings unique cross-sector expertise to discussions on healthcare innovation, women's health equity, and the future of personalised medicine.

Professor John Skerritt AM is Enterprise Professor in Health Research Impact at the University of Melbourne, advising academics and the university on commercial and policy translation of their research portfolio.

In April 2023 Prof Skerritt retired as Deputy Secretary of the Australian Department of Health and Aged Care, with responsibility for the Therapeutic Goods Administration, regulation of gene technology and industrial chemicals and control of drug import, export and production. In addition, he was part of the Department’s executive team leading policy development and implementation for Australia’s health and aged care system for over 10 years. He has extensive experience in government and working with ministers, having been a Deputy Secretary/Agency head for 24 years.

Prof Skerritt was previously the most senior scientific leader in Australia’s Foreign Affairs portfolio, lading implementation of more than $1 billion in collaborative scientific programs between Australia and regional countries. More recently he helped lead Australia’s COVID-19 response and was one of the public media faces of the response. He also played a major role in advising the Australian government on the establishment of a mRNA vaccines and medicines industry.

Prof Skerritt has a PhD in pharmacology, is author of over 300 publications and 10 patents and has commercialised a dozen IVD and protein fractionation products internationally. He is a Non-executive Director of AusBiotech Limited and Medicines Australia and is currently Chair of the Scientific Advisory Council of the UK-based Centre for Innovation in Regulatory Science and is a member of the Board of the Singapore-based Centre for Regulatory Excellence.

In more than 20 years of consulting and leadership in APAC, Ravi’s expertise has focused on helping clients take big-bet investments in complex and uncertain environments at an asset and  portfolio levels. Ravi regularly advises clients on their most critical challenges: decisions to enter new markets, and optimize their portfolios and R&D investments.

He has also supervised many multi-year programs for clients that resulted in significant increases in shareholder value while bringing lasting transformation in their organizations.

Ravi holds a bachelor’s degree in Technology from Indian Institute of Technology, Chennai, and an MBA from the Indian Institute of Management, Calcutta.

Dr Michelle Perugini is an entrepreneur with extensive experience in healthcare and advanced AI technologies. Michelle is an avid supporter of the AI and women’s health sectors globally, and Winner of the 2021 Women in AI (WAI) Healthcare and Telstra Brilliant Women in Digital Health Awards. She has a PhD in Medicine and was a post-doctoral research fellow in Oncology for a decade. She has founded 2 global AI tech companies, the first of which was acquired by EY in 2015.

‍
Michelle was most recently the Co-Founder and CEO of Presagen, an AI healthcare company that has developed a novel Decentralized Federated AI platform that can safely train on medical data distributed all around the world, without the need to physically move (centralized) or manually view private patient data. Presagen’s flagship product suite, Life Whisperer, uses AI to assess images of embryos and eggs (oocytes) to improve IVF outcomes for couples struggling with fertility. Life Whisperer was authorized for sale in 47 countries prior to being acquired by global IVF manufacturer Astec in 2024.

‍
In 2024, Presagen merged with Qubist to form Qubigen, a company focused on AI driven drug design, where Michelle is a Co-Founder and Board Chair.
Michelle is currently Head of Commercialisation at University of South Australia, and CEO of UniSA Ventures.

Mohamed (Mo) Dirani is an Australian entrepreneur, scientist, and the founder of Plano Pte Ltd, an award-winning Healthtech startup based in Singapore. Plano leverages patent protected technological solutions, educational tools, and AI to address short-sightedness in children. Mo served as the company’s Founding Managing Director from August 2017 to March 2024 and now holds the position of Chair of the Plano Board, while also being an active member of its Science and Innovation Advisory Group.

Plano’s investors include prominent Singaporean government entities, angel investors, venture capitalists, and one of the world’s leading ophthalmic pharmaceutical companies, Santen. Throughout his tenure, Mo demonstrated exceptional leadership and business acumen, successfully securing seed to Series B funding and driving the company’s growth across Singapore, Southeast Asia, and China, where Plano’s strategic expansion is currently focused. He was pivotal in transitioning the company from concept to commercialization, becoming a key first mover in both local and international markets.

In addition to his entrepreneurial accomplishments, Mo has maintained academic roles at prestigious medical research institutes and universities. He is an Adjunct Associate Professor at the Duke-NUS Medical School, as well as an honorary Principal Investigator at the Singapore Eye Research Institute (SERI) and the Centre for Eye Research Australia (CERA).